Therefore, imatinib or dasatinib could represent a treatment option for 8,500–17,000 patients with lung cancer globally that harbor mutations in ABL1 (http://globocan.iarc.fr/old/FactSheets/cancers/lung-new.asp). This evidence concerns the gene ABL1 and lung cancer.